Europe Temporal Arteritis Market was valued at USD 1.1 Billion in 2022 and is projected to reach USD 1.8 Billion by 2030, growing at a CAGR of 6.4% from 2024 to 2030.
The European market for Giant Cell Arteritis (GCA) treatments has experienced significant growth in recent years, driven by advancements in therapeutic options and a heightened understanding of the disease. As of 2023, the market was valued at approximately USD 1.08 billion, with projections suggesting an increase to USD 1.63 billion by 2030, reflecting a compound annual growth rate (CAGR) of 6%. citeturn0search1
**Key Market Segments**
Therapeutics: Corticosteroid therapies remain the cornerstone of GCA treatment, though the demand for immunosuppressive agents and biologics like tocilizumab is on the rise. citeturn0search7
Route of Administration: Oral administration dominates, but intravenous and subcutaneous routes are gaining acceptance, particularly for biologic treatments.
End-Users: Hospitals and specialty clinics are primary treatment settings, but homecare services are expanding due to patient preference for at-home care.
Distribution Channels: Hospital pharmacies lead in distribution, with online and retail pharmacies experiencing growth as patients seek convenient access to medications.
**Industry Requirements and Opportunities**
Pharmaceutical companies are actively developing novel therapies to address unmet needs in GCA treatment. The approval of tocilizumab by the European Commission in 2017 opened new avenues for patients, highlighting the importance of regulatory approvals in expanding treatment options. citeturn0search7
There is a growing demand for personalized medicine approaches, as treatments tailored to individual patient profiles can enhance efficacy and reduce adverse effects. Additionally, the increasing geriatric population in Europe presents both a challenge and an opportunity, necessitating more healthcare resources and specialized treatments for age-related conditions like GCA.
Collaboration among healthcare providers, researchers, and pharmaceutical companies is crucial to advance understanding and management of GCA. Investments in research and development, along with a focus on patient-centered care, are essential to meet the evolving needs of the European GCA market.
Get an In-Depth Research Analysis of the Europe Temporal Arteritis Market Size And Forecast [2025-2032]
Â
Novartis AG
Endo International Inc
Teva Pharmaceutical Industries Ltd
Glenmark Pharmaceuticals Ltd
Cipla Inc
Dr Reddy's Laboratories Ltd
Abbott
F. Hoffmann -La Roche Ltd
Pfizer Inc
Zydus Group
Lupin
Amorphex Therapeutics Holdings
Inc
Bausch Health Companies Inc
Regeneron Pharmaceuticals Inc
Astellas Pharma Inc
Â
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the Europe Temporal Arteritis Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the Europe Temporal Arteritis Market
Clinical Diagnosis
Biopsy
Imaging Techniques
Corticosteroids
Immunosuppressive Drugs
Biologic Drugs
Hospitals
Specialty Clinics
Ambulatory Surgical Centers
Giant Cell Arteritis
Non-Giant Cell Arteritis
Oral
Injectable
US (United States, US and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ Temporal Arteritis Market Research Analysis
1. Introduction of the Europe Temporal Arteritis Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. Europe Temporal Arteritis Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. Europe Temporal Arteritis Market, By Type
6. Europe Temporal Arteritis Market, By Application
7. Europe Temporal Arteritis Market, By Geography
US
Europe
Asia Pacific
Rest of the World
8. Europe Temporal Arteritis Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Europe Research and Consulting firm servicing over 5000+ US clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/